Sandoz resolves patent litigation with Amgen, paving the way for the launch of denosumab biosimilars Jubbonti and Wyost.

Sandoz US, settles Generic Pharmaceuticals Pricing Antitrust Litigation for $265 million, addressing claims from direct purchas...

Coherus BioSciences agreed to sell its ophthalmology franchise for $170M to Sandoz. This aligns with CHRS' focus on oncolog...

Major pharmaceutical firms, including generic manufacturers such as Teva Pharmaceutical Industries Limited (NYSE: TEVA), Sandoz...

Novartis AG (NYSE: NVS) has outlined the progress made in delivering its pure-play strategy, focused on four core therapeutic a...

Sandoz Group AG (OTC: SDZNY) (OTC: SDZXF) enters a new era as a standalone player in generic and biosimilar medicines.